Department of Hematology, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Department of Hematology, Hospital General Regional No 72, Instituto Mexicano del Seguro Social, Ciudad de México, Estado de México, México.
Curr Oncol Rep. 2022 May;24(5):645-650. doi: 10.1007/s11912-021-01169-w. Epub 2022 Feb 26.
COVID-19 is highly contagious; since it was first identified, the virus has rapidly spread to more than 100 countries and was declared a pandemic on March 11, 2020, by the World Health Organization (WHO). This disease presents several challenges when managing patients with leukemia. We review the information about chronic myeloid leukemia (CML) and COVID-19: risk factors, prognosis, and the role of tyrosine kinase inhibitors (TKIs).
At present, we find no data suggesting that patients with CML-chronic phase (CML-CP) are at higher risk of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general healthy population. TKIs had been proposed to fight the SARS-CoV-2-related disease (COVID-19). CML patients should continue receiving their TKIs if they have COVID-19 disease. The role of TKIs as protective factors against SARS-CoV-2 infection in patients with CML should be confirmed by large-scale epidemiologic studies.
COVID-19 具有高度传染性；自首次发现以来，该病毒已迅速传播到 100 多个国家，并于 2020 年 3 月 11 日被世界卫生组织（WHO）宣布为大流行。在管理白血病患者时，该疾病带来了诸多挑战。我们回顾了有关慢性髓性白血病（CML）和 COVID-19 的信息：危险因素、预后以及酪氨酸激酶抑制剂（TKI）的作用。
目前，我们没有发现数据表明慢性期 CML（CML-CP）患者比一般健康人群更容易感染严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）。TKI 被提议用于对抗与 SARS-CoV-2 相关的疾病（COVID-19）。如果 CML 患者患有 COVID-19 疾病，应继续接受 TKI 治疗。TKI 是否作为 CML 患者对抗 SARS-CoV-2 感染的保护因素，应通过大规模的流行病学研究来证实。
